These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 26690748)
1. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. Kim W; Ryan CJ J Comp Eff Res; 2016 Jan; 5(1):5-7. PubMed ID: 26690748 [No Abstract] [Full Text] [Related]
3. Strategies for targeting the androgen receptor axis in prostate cancer. Carver BS Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669 [TBL] [Abstract][Full Text] [Related]
4. Leading causes of castration-resistant prostate cancer. Lu M; Lu H; Kong Q Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203 [TBL] [Abstract][Full Text] [Related]
11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
13. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Kim W; Ryan CJ Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176 [TBL] [Abstract][Full Text] [Related]
14. Emerging agents for the therapy of advanced prostate cancer. Hathaway AR; Baker MK; Sonpavde G Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474 [TBL] [Abstract][Full Text] [Related]